AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Tubulin polyglutamylase TTLL5

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q6EMB2

UPID:

TTLL5_HUMAN

Alternative names:

SRC1 and TIF2-associated modulatory protein; Tubulin--tyrosine ligase-like protein 5

Alternative UPACC:

Q6EMB2; B9EGH8; B9EGH9; Q9BUB0; Q9H0G4; Q9H7W2; Q9P1V5; Q9UPZ4

Background:

Tubulin polyglutamylase TTLL5, also known as SRC1 and TIF2-associated modulatory protein, plays a crucial role in modifying tubulin. This enzyme generates polyglutamate side chains on tubulin, essential for proper cellular function. It shows a preference for initiating over elongating the polyglutamylation reaction and modifies alpha-tubulin more than beta-tubulin. TTLL5 is vital for CCSAP localization to microtubules and enhances NCOA2/TIF2's effects in hormone receptor signaling.

Therapeutic significance:

TTLL5's mutation is linked to Cone-rod dystrophy 19, a retinal dystrophy leading to severe vision loss. Understanding TTLL5's role could unveil new therapeutic strategies for this and potentially other related diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.